Dear Sir,

With the increasing prevalence of coronavirus disease-19 (COVID-19) infection worldwide, early detection has become crucial to ensure rapid prevention and timely treatment. However, due to the unknown gene sequence of the supposed coronavirus, the reference standard test has not been established for diagnosis \[[@bb0005]\]. Several methods have been established for prompt detection of the genetic sequence of COVID-19 nucleic acid such as real-time reverse-transcriptase polymerase chain reaction (RT-PCR). However, this test is not readily available everywhere, especially in developing countries. In addition, its results are not typically readily available, requiring multiple hours for the result \[[@bb0010]\].
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Some studies have reported that chest CT images have the sensitivity of 80--90% and specificity of 82.8--96% for detecting the lung lesions in patients with COVID-19 (area under the receiver operating characteristic curve, ranged between 0.87 and 0.96) \[[@bb0020],[@bb0100]\]. Accordingly, the findings of the available studies support the use of chest CT scan as a reliable test for detecting pulmonary lesions related to the COVID-19 infection. Some studies have reported that chest CT manifestations may associate with the progression and prognosis of COVID-19 \[[@bb0095]\].

Timely detection of COVID-19 patients is of crucial importance, particularly in those with false-negative RT-PCR or those without symptoms. Given the large global outbreak of COVID-19 infection, limited availability of COVID-19 nucleic acid detection kit, nonspecific clinical manifestations as well as unavailability of reliable standalone tool to rule out COVID-19 infection, performing chest CT may be a helpful test for patients suspected of COVID-19 infection at the beginning of admission in the emergency department. In this context, detecting bilateral, multifocal and peripherally distributed ground-glass opacities with or without consolidation could be a valuable diagnostic clue. These findings were considered highly suspicious of COVID-19 infection; however, these findings can be further confirmed by positive real-time RT-PCR assay for COVID-19 infection.

An important issue is that excessive demand for CT imaging of patient with COVID-19 not only increases costs, but also pose significant risk for transmission or environmental contamination. Therefore, there are several significant considerations for both emergency and radiology departments during the work-up of each patient with COVID-19 that impact use of chest CT, including the safety of personnel, the decontamination of radiology equipment, and the duration of CT room unavailability. Among these cases, the length of time the CT device is out of service has a significant role in increasing the waiting time for performing CT scan and then increasing the emergency department crowding. Currently, there are no valid guidelines for determining the time interval for subsequent patients. However, between 30 min and 1 h of room downtime is recommended for environmental cleaning and equipment decontamination using hospital approved methods such as hydrogen peroxide vapor, ultraviolet light, Phenolic or sodium hypochlorite \[[@bb0105],[@bb0110]\]. Accordingly, it is recommended that CT imaging be reserved for emergent cases with suspected COVID-19 infection. As a general rule, standardized infection control and prevention practices should be implemented for all patients with respiratory illness \[[@bb0115]\]. Protecting radiology personnel from the hazard posed by a patient with COVID-19 involves employing droplet precaution, using appropriate personal protective equipment, limiting the number of staff entering the patient\'s room, and careful screening of staff to identify possible cases. Environmental decontamination of CT rooms could be achieved thorough cleaning of surfaces with common chemical disinfectants, such as sodium hypochlorite, Phenolic, bleach, hydrogen peroxide, or quaternary ammonium compounds, by someone with appropriate protective equipment, maintaining proper ventilation and airflow in the CT scanner rooms and putting CT equipment out of commission for specific time for cleaning. In this regard, United States Environmental Protection Agency published some registered disinfectants for use against COVID-19 (available at: <https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2>). In addition, chest CT imaging should be performed at sites with less traffic to avoid uninfected patient and staff exposure. Portable chest X-ray in patient rooms, radiology outposts, and isolated CT imaging rooms are options, if available, to limit contamination of radiology equipment and environment \[[@bb0110]\]. Undoubtedly, performing these protective measures may reduce access to CT imaging suites, leading problems for patient care, especially critically ill patients.
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